The stock price of Ideaya Biosciences Inc (NASDAQ: IDYA) has jumped by 0.49 compared to previous close of 18.51. Despite this, the company has seen a fall of -4.07% in its stock price over the last five trading days. prnewswire.com reported 2025-03-03 that SOUTH SAN FRANCISCO, Calif., March 3, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced a research collaboration with ATTMOS as part of its efforts to build a physics-based computational small molecule discovery platform that rapidly unlocks what are currently perceived as undruggable oncology targets.
Is It Worth Investing in Ideaya Biosciences Inc (NASDAQ: IDYA) Right Now?
The 36-month beta value for IDYA is at 0.46. Analysts have varying views on the stock, with 11 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IDYA is 80.75M, and currently, shorts hold a 11.38% of that float. The average trading volume for IDYA on March 13, 2025 was 899.23K shares.
IDYA’s Market Performance
IDYA’s stock has seen a -4.07% decrease for the week, with a -17.04% drop in the past month and a -33.07% fall in the past quarter. The volatility ratio for the week is 6.36%, and the volatility levels for the past 30 days are at 5.56% for Ideaya Biosciences Inc. The simple moving average for the past 20 days is -7.37% for IDYA’s stock, with a -40.16% simple moving average for the past 200 days.
Analysts’ Opinion of IDYA
Many brokerage firms have already submitted their reports for IDYA stocks, with Stephens repeating the rating for IDYA by listing it as a “Overweight.” The predicted price for IDYA in the upcoming period, according to Stephens is $51 based on the research report published on November 18, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see IDYA reach a price target of $27. The rating they have provided for IDYA stocks is “Market Perform” according to the report published on November 05th, 2024.
UBS gave a rating of “Buy” to IDYA, setting the target price at $50 in the report published on October 24th of the previous year.
IDYA Trading at -16.89% from the 50-Day Moving Average
After a stumble in the market that brought IDYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.91% of loss for the given period.
Volatility was left at 5.56%, however, over the last 30 days, the volatility rate increased by 6.36%, as shares sank -13.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.07% lower at present.
During the last 5 trading sessions, IDYA fell by -4.07%, which changed the moving average for the period of 200-days by -55.05% in comparison to the 20-day moving average, which settled at $20.08. In addition, Ideaya Biosciences Inc saw -27.63% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IDYA starting from Jason Throne, who proposed sale 75,000 shares at the price of $40.22 back on Aug 26 ’24. After this action, Jason Throne now owns shares of Ideaya Biosciences Inc, valued at $3,016,500 using the latest closing price.
WHITE MICHAEL ANTHONY, the Chief Scientific Officer of Ideaya Biosciences Inc, sale 28,500 shares at $36.24 during a trade that took place back on May 29 ’24, which means that WHITE MICHAEL ANTHONY is holding 0 shares at $1,032,884 based on the most recent closing price.
Stock Fundamentals for IDYA
Current profitability levels for the company are sitting at:
- -46.71 for the present operating margin
- 0.69 for the gross margin
The net margin for Ideaya Biosciences Inc stands at -39.21. The total capital return value is set at -0.3. Equity return is now at value -32.67, with -30.95 for asset returns.
Based on Ideaya Biosciences Inc (IDYA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -12.91.
Currently, EBITDA for the company is -326.98 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 223.28. The receivables turnover for the company is 2333.33for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.97.
Conclusion
In conclusion, Ideaya Biosciences Inc (IDYA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
